The Global Market for DPP-IV Inhibitors is Projected to Reach US$14.8 Billion by 2022

Rising Epidemic of Type-2 Diabetes Mellitus Drives the Global DPP-IV Inhibitors Market, According to a New Report by Global Industry Analysts, Inc.

GIA launches comprehensive analysis of industry segments, trends, growth drivers, market share, size and demand forecasts on the global DPP-IV Inhibitors market. The global market for DPP-IV Inhibitors is projected to reach US$14.8 billion by 2022, driven by the increasing incidence of diabetes and demand for novel therapies with excellent safety profiles, convenient dosage regimens, and minimal side-effects.

DPP-IV inhibitors inhibit the DiPeptidyl Peptidase IV (DPP-4) enzyme and enhance the action of its substrate, the incretin hormones, which then aid in increased insulin release and maintain appropriate glucose levels in the blood. DPP-IV inhibitors, also called “gliptins”, primarily include Sitagliptin (brand names Januvia, Janumet), Vildagliptin (Galvus), Saxagliptin (Onglyza) and others such as Linagliptin, Alogliptin and Teneligliptin. Gliptins represent an attractive alternative to the first-line therapy of metformin for diabetes, especially in people who cannot tolerate biguanide metformin hydrochloride because of adverse gastrointestinal effects, and in whom metformin-only therapy is not effective. DPP-4 inhibitors made their way into the market in 2006, with the U.S. launch of the first drug in the class, Januvia. Excellent safety profile of the drug and the convenience of being an oral drug with once-daily dosage, led to tremendous success of the drug since its launch. Despite being well tolerated and having an excellent safety profile, most DPP-4 inhibitors are yet to be established with respect to durability of their effects. As a result, outcomes of long-term studies remain vital for the continued growth of these medications.

Safety warnings added to gliptin drug labels of late may threaten the market to an extent. In 2015, the FDA added a Warning and Precaution about the risk of severe and disabling joint pain to the labels of all DPP-4 inhibitors, based on adverse event reports. Further, in 2016, a FDA safety review found that saxagliptin and alogliptin-containing drugs may increase heart failure risk, particularly in heart or kidney disease patients. Consequently, new warnings about heart failure risk were added to drug labels of saxagliptin and alogliptin drugs, marketed under the trade names of Onglyza, Kombiglyze-XR, Nesina, Kazano & Oseni. Despite the availability of an increasing number of drugs, management of type2 diabetes-associated hyperglycemia is challenging. Dipeptidyl Peptidase-4 Inhibitors offer some advantages over conventional sulfonylureas, in terms of weight management of diabetic patients. But the recent launch of two Sodium–Glucose  Co-Transporter type 2 (SGLT2) inhibitors, Dapagliflozin and Canagliflozin, and the impending launch of the third one, Empagliflozin, will increase competition in the anti-diabetic drug space.

As stated by the new market research report on DPP-IV Inhibitors, the United States represents the largest market worldwide. Asia-Pacific ranks as the fastest growing market worldwide, with a CAGR of 13.8% over the analysis period. The growth in the region is backed by China and India with their huge type-2 diabetic and pre-diabetic population.

Major players covered in the report include AstraZeneca Plc., Boehringer Ingelheim GmbH, Eli Lilly and Company, Merck & Co. Inc., Mitsubishi Tanabe Pharma Corporation, Novartis AG, and Takeda Pharmaceutical Company Limited.

The research report titled "DPP-IV Inhibitors: A Global Strategic Business Report" announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, growth drivers, mergers and acquisitions, and other strategic industry activities of major companies worldwide. The report provides market estimates and projections for geographic markets, such as the US, Canada, Japan, Europe (France, Germany, Italy, UK, Russia, and Rest of Europe), Asia-Pacific (China, India, South Korea, and Rest of Asia-Pacific), and Rest of World. Drug compound segments analyzed for the global market include sitagliptin, vildagliptin, saxagliptin, and others (including alogliptin and linagliptin). Drug segments analyzed for the US market include sitagliptin, saxagliptin, linagliptin, and alogliptin.  

Global Industry Analysts, Inc. 6150 Hellyer Ave., San Jose CA 95138, USA, All Rights Reserved.